首页> 美国卫生研究院文献>other >Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

【2h】

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

机译：I期研究评估低剂量胞嘧啶阿拉伯糖苷与Barasertib（AZD1152）在老年AML患者中的安全性和耐受性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionBarasertib is the pro-drug of barasertib-hQPA, a selective Aurora B kinase inhibitor that has demonstrated preliminary anti-acute myeloid leukemia (AML) activity in the clinical setting.

机译：简介Barasertib是barasertib-hQPA的前药，barasertib-hQPA是一种选择性的Aurora B激酶抑制剂，已在临床环境中显示出初步的抗急性髓性白血病（AML）活性。

著录项

期刊名称 other
作者
Hagop M Kantarjian; Mikkael A Sekeres; Vincent Ribrag; Philippe Rousselot; Guillermo Garcia-Manero; Elias J Jabbour; Kate Owen; Paul K Stockman; Stuart D Oliver;
展开▼
作者单位

展开▼
年(卷),期 -1(13),5
年度 -1
页码 559–567
总页数 17
原文格式 PDF
正文语种
中图分类
关键词
Acute myeloid leukemia barasertib-hQPA dose-escalation study;

机译：急性粒细胞白血病;barasertib-hQPA;剂量递增研究;

相似文献

外文文献
中文文献
专利

1. Stage i of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia [J] . KantarjianH.M., MartinelliG., JabbourE.J., Cancer: A Journal of the American Cancer Society . 2013,第14期

机译：评估Barasertib（AZD1152）与低剂量胞嘧啶阿拉伯糖苷在老年急性髓样白血病患者中的疗效，安全性和耐受性的第二阶段研究的第一阶段
2. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. [J] . Lowenberg B, Muus P, Ossenkoppele G, Blood: The Journal of the American Society of Hematology . 2011,第23期

机译：1/2期研究评估了Barasertib（AZD1152）在晚期急性髓样白血病患者中的安全性，疗效和药代动力学。
3. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. [J] . Tsuboi K, Yokozawa T, Sakura T, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2011,第10期

机译：一期研究评估了Aurora B激酶抑制剂Barasertib（AZD1152）在日本晚期急性髓样白血病患者中的安全性，药代动力学和疗效。
4. Preclinical studies of S1 in K562 cell line and primary chronic myeloid leukemia cells shown synergistic effect with Cytosine Arabinoside Hydrochloride [C] . Chen WenJuan, Zhang ZhiChao, Han Wei, 2010 3rd International Conference on Biomedical Engineering and Informatics . 2010

机译：在K562细胞系和原发性慢性髓性白血病细胞中进行S1的临床前研究显示，它们与盐酸胞嘧啶阿拉伯糖苷具有协同作用
5. The safety and tolerability of regadenoson in patients with end stage renal disease. [D] . Rangel, Maria Octavia. 2013

机译：regadenoson在晚期肾病患者中的安全性和耐受性。
6. Stage I of Phase II study assessing efficacy safety and tolerability of barasertib (AZD1152) versus LDAC in elderly AML patients [O] . Hagop M Kantarjian, Giovanni Martinelli, Elias J Jabbour, -1

机译：评估Barasertib（AZD1152）与LDAC在老年AML患者中的疗效安全性和耐受性的II期研究的第一阶段
7. Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML [O] . Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag, 2013

机译：I阶段研究评估Barasertib（AZD1152）与低剂量胞嘧啶Arabinoside在老年AML患者中的安全性和耐受性

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

摘要

著录项

相似文献

相关主题

期刊订阅